Medical staff prepare an injection of Jynneos monkeypox vaccine, developed by Danish pharmaceutical company Bavarian Nordic, in Los Angeles, California, USA. Photo: Getty Images/VNA
|
The prequalification approval is expected to facilitate timely and increased access to this vital product in communities with urgent need, to reduce transmission and help contain the outbreak, the WHO said.
WHO’s assessment for prequalification is based on information submitted by the manufacturer, Bavarian Nordic A/S, and review by the European Medicines Agency, the regulatory agency of record for this vaccine.
“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.